This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Athenahealth Defended After Einhorn Short Call Sinks Stock

NEW YORK (TheStreet) -- After well-known investor David Einhorn yesterday predicted that the shares of athenahealth (ATHN) could tumble 80% and said he was shorting the stock, several research firms defended the company and its outlook in notes to investors earlier today. Athenahealth provides an Internet-based practice management solution to medical practices.

BULLISH TAKE: Athenahealth is not a software company, but an outsourcing company, and expectations for its operating margins are too high, said Einhorn, the president of hedge fund Greenlight Capital. Moreover, the company will not be able to effectively compete against larger players in the space, Einhorn contended during his presentation at the Ira Sohn investor conference.

ANALYST DEFENSES: One firm contesting Einhorn's thesis in a note to investors earlier today was Citigroup. athenahealth is a software-as-a-service company, since it provides cloud-based products that are largely automated and purchased by its customers for a year at a time, wrote Citi analyst Garen Sarafian. Athenahealth's margins are in-line with its SAAS peers and they should rise as the company's marginal costs decline, while the company has minimal upfront costs, Sarafian said. Additionally, there is room for both athenahealth and competitor Epic to win in the space, added the analyst, who kept a $200 price target and Buy rating on athenahealth. PiperJaffray analyst Sean Wieland was even more upbeat, saying that the stock has reached its best entry point in years. Athenahealth is more than just an outsourcing company and it does not compete head-to-head with Epic, which focuses on the hospital sector, according to the Piper analyst. He reiterated a $220 price target and Overweight rating on the shares.

BEARISH TAKE: Conversely, David Francis, an analyst at RBC Capital, wrote that Einhorn's theories about the challenges facing athenahealth will prove to be largely correct over the longer term. However, the company will have several positive catalysts in the near-term, including strong demand from smaller medical offices for the company's systems, the possibility that the company could announce several deals with larger enterprises, and the disclosure of additional partners for its Enterprise Coordinator inpatient management system, Francis forecast. Although Francis thinks these near-term events "are likely to give bulls a shot in the arm," he kept a Sector Perform rating on the shares due to what he sees as the longer term issues facing the company.

WHAT'S NOTABLE: In slides ahead of its presentation today at Baird's 2014 Growth Stock conference, athenahealth repeated its FY14 adjusted earnings per share outlook of 98c-$1.10 and its revenue view of $725M-$755M.

PRICE ACTION: In early trading, athenahealth sank $15.88, or 12.5%, to $110.90. Reporting by Larry Ramer.

The Fly provides comprehensive coverage of stock news and Street research and delivers it in real-time. The Fly breaks market-moving news and explains sudden stock movements in a rapid-fire, short-form story format. Follow @theflynews on Twitter. For a free trial, click here.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%
TSLA $280.02 0.00%
YHOO $39.38 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs